10-Q
30falseQ300016565360.1886--12-310001656536us-gaap:RetainedEarningsMember2021-12-310001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001656536us-gaap:AdditionalPaidInCapitalMember2021-12-310001656536dbtx:TwoThousandAndFifteenStockIncentivePlanMember2022-09-300001656536us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001656536us-gaap:EmployeeStockOptionMember2021-12-310001656536us-gaap:IPOMember2021-02-170001656536us-gaap:RetainedEarningsMember2021-07-012021-09-300001656536us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001656536us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001656536dbtx:SeriesCConvertiblePreferredStockMember2021-01-012021-03-310001656536us-gaap:AdditionalPaidInCapitalMember2021-03-310001656536dbtx:USAgencyBondsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001656536dbtx:TwoThousandAndTwentyOneStockIncentivePlanMemberus-gaap:IPOMember2022-09-300001656536srt:MaximumMemberus-gaap:CommonStockMember2022-03-012022-03-310001656536dbtx:SeriesBConvertiblePreferredStockMember2021-01-012021-03-310001656536us-gaap:RetainedEarningsMember2022-01-012022-03-310001656536us-gaap:FairValueInputsLevel2Memberdbtx:USAgencyBondsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001656536us-gaap:AccountingStandardsUpdate202110Member2022-09-300001656536us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001656536us-gaap:BuildingMemberdbtx:SubleaseAgreementMember2022-01-310001656536srt:MaximumMember2022-09-3000016565362021-01-012021-12-3100016565362020-11-012020-11-3000016565362021-12-310001656536us-gaap:CommonStockMember2021-03-310001656536dbtx:TwoThousandAndTwentyOneStockIncentivePlanMemberus-gaap:IPOMember2021-12-3100016565362021-06-300001656536us-gaap:RetainedEarningsMember2022-07-012022-09-300001656536us-gaap:AccountingStandardsUpdate201912Member2022-09-300001656536srt:ScenarioForecastMember2022-10-012022-12-3100016565362017-11-300001656536us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001656536us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001656536us-gaap:CommonStockMember2021-04-012021-06-300001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001656536us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001656536us-gaap:CommonStockMember2020-12-310001656536us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001656536dbtx:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember2022-01-012022-09-300001656536dbtx:TwoThousandAndTwentyOneStockIncentivePlanMember2021-12-310001656536dbtx:USAgencyBondsMemberdbtx:CurrentMember2021-12-3100016565362022-04-012022-06-3000016565362020-10-012020-10-310001656536us-gaap:RetainedEarningsMember2022-03-310001656536us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001656536us-gaap:RetainedEarningsMember2022-06-300001656536us-gaap:RestrictedStockUnitsRSUMember2022-09-3000016565362022-11-010001656536dbtx:TwoThousandAndTwentyOneStockIncentivePlanMemberus-gaap:IPOMember2022-01-012022-01-010001656536us-gaap:EmployeeStockOptionMember2022-09-300001656536srt:MaximumMemberdbtx:AtTheMarketOfferingMember2022-08-012022-08-310001656536dbtx:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember2022-09-300001656536us-gaap:AdditionalPaidInCapitalMember2020-12-310001656536dbtx:SeriesDConvertiblePreferredStockMember2021-01-012021-03-310001656536dbtx:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember2022-01-012022-01-010001656536us-gaap:CommonStockMember2022-01-012022-09-300001656536dbtx:UnvestedRestrictedStockAwardsMember2021-01-012021-09-300001656536us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001656536us-gaap:CommonStockMember2021-07-012021-09-300001656536dbtx:TwoThousandAndTwentyOneStockIncentivePlanMemberus-gaap:IPOMember2022-01-012022-09-300001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001656536us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001656536us-gaap:AdditionalPaidInCapitalMember2021-09-300001656536us-gaap:RetainedEarningsMember2021-06-300001656536dbtx:SeriesAConvertiblePreferredStockMember2021-01-012021-03-310001656536dbtx:USAgencyBondsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001656536dbtx:CurrentMember2021-12-310001656536dbtx:USAgencyDiscountNotesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001656536us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001656536us-gaap:CommonStockMember2021-09-300001656536us-gaap:RetainedEarningsMember2021-01-012021-03-310001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001656536us-gaap:FairValueInputsLevel2Memberdbtx:USAgencyBondsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001656536us-gaap:CorporateDebtSecuritiesMemberdbtx:CurrentMember2021-12-310001656536dbtx:OfficeAndLaboratorySpaceMemberdbtx:SubleaseAgreementMember2021-05-012021-05-310001656536us-gaap:AdditionalPaidInCapitalMember2022-06-300001656536us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001656536dbtx:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember2021-12-3100016565362021-07-012021-09-300001656536dbtx:UnvestedRestrictedStockUnitsMember2022-07-012022-09-300001656536dbtx:CurrentMemberus-gaap:USTreasurySecuritiesMember2021-12-3100016565362021-01-012021-03-3100016565362021-02-242021-02-240001656536us-gaap:AdditionalPaidInCapitalMember2022-03-310001656536us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001656536dbtx:LaboratoryEquipmentMember2020-07-310001656536us-gaap:RestrictedStockMember2022-09-3000016565362020-12-310001656536us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001656536us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001656536us-gaap:EmployeeStockOptionMember2021-07-012021-09-3000016565362021-09-300001656536us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001656536us-gaap:RetainedEarningsMember2021-09-300001656536dbtx:OfficeAndLaboratorySpaceMemberdbtx:SubleaseAgreementMember2021-01-012021-01-310001656536us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001656536us-gaap:RestrictedStockMembersrt:MaximumMember2022-09-300001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001656536us-gaap:BuildingMemberdbtx:SubleaseAgreementMember2019-09-012019-09-300001656536dbtx:NoncurrentMemberus-gaap:USTreasurySecuritiesMember2021-12-3100016565362022-03-310001656536dbtx:SeriesDConvertiblePreferredStockMember2020-12-310001656536dbtx:NoncurrentMember2021-12-310001656536dbtx:UnvestedRestrictedStockAwardsMember2022-07-012022-09-300001656536us-gaap:CommercialPaperMemberdbtx:CurrentMember2021-12-310001656536dbtx:CurrentMember2022-09-3000016565362021-01-012021-09-300001656536us-gaap:CommonStockMember2022-06-300001656536us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001656536us-gaap:AdditionalPaidInCapitalMember2021-06-300001656536us-gaap:RetainedEarningsMember2021-03-310001656536us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-3000016565362022-01-010001656536us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-3000016565362021-03-310001656536dbtx:SeriesCConvertiblePreferredStockMember2020-10-310001656536us-gaap:FairValueMeasurementsRecurringMember2021-12-310001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001656536dbtx:TwoThousandAndTwentyOneStockIncentivePlanMember2022-09-300001656536us-gaap:CommonStockMember2022-09-300001656536us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001656536us-gaap:BuildingMemberdbtx:SubleaseAgreementMember2019-09-300001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001656536us-gaap:FairValueMeasurementsRecurringMember2022-09-300001656536us-gaap:CommonStockMember2022-07-012022-09-300001656536us-gaap:RestrictedStockMembersrt:MaximumMember2022-01-012022-09-300001656536dbtx:SeriesBConvertiblePreferredStockMember2020-12-310001656536us-gaap:CommonStockMember2021-06-300001656536us-gaap:IPOMember2021-02-172021-02-170001656536us-gaap:RetainedEarningsMember2022-09-300001656536us-gaap:RestrictedStockMember2022-01-012022-09-300001656536us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001656536dbtx:AtTheMarketOfferingMemberus-gaap:CommonStockMember2022-01-012022-09-300001656536dbtx:TwoThousandAndFifteenStockIncentivePlanMember2021-12-310001656536us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001656536us-gaap:RestrictedStockMember2021-12-310001656536us-gaap:CommonStockMember2021-02-052021-02-050001656536dbtx:CurrentMemberus-gaap:USTreasurySecuritiesMember2022-09-3000016565362021-04-012021-06-300001656536dbtx:LaboratoryEquipmentMember2020-07-012020-07-3100016565362022-09-300001656536us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001656536us-gaap:AccountingStandardsUpdate201602Member2022-09-300001656536us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-3100016565362022-01-012022-09-300001656536dbtx:SeriesCConvertiblePreferredStockMember2020-12-310001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001656536us-gaap:RetainedEarningsMember2021-04-012021-06-3000016565362022-07-012022-09-300001656536us-gaap:CommonStockMember2021-12-310001656536us-gaap:CommonStockMemberdbtx:AtTheMarketOfferingMember2022-09-300001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001656536dbtx:UnvestedRestrictedStockAwardsMember2021-07-012021-09-300001656536us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001656536us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-3100016565362016-07-012016-07-310001656536us-gaap:SeriesCPreferredStockMember2022-09-300001656536us-gaap:CommonStockMember2022-03-310001656536us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-3000016565362016-07-310001656536us-gaap:AdditionalPaidInCapitalMember2022-09-300001656536us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001656536us-gaap:FairValueInputsLevel2Memberdbtx:USAgencyDiscountNotesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001656536dbtx:RegeneronAgreementMember2022-09-3000016565362022-01-012022-03-310001656536us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001656536dbtx:UnvestedRestrictedStockAwardsMember2022-01-012022-09-300001656536us-gaap:RetainedEarningsMember2020-12-310001656536us-gaap:OverAllotmentOptionMember2021-02-242021-02-2400016565362021-10-012021-10-310001656536us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000016565362022-06-300001656536us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001656536srt:MaximumMember2020-10-310001656536dbtx:OfficeAndLaboratorySpaceMemberdbtx:SubleaseAgreementMember2020-01-310001656536us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001656536us-gaap:CommonStockMember2021-01-012021-03-310001656536us-gaap:BuildingMemberdbtx:SubleaseAgreementMember2022-01-012022-01-310001656536dbtx:OfficeAndLaboratorySpaceMemberdbtx:SubleaseAgreementMember2020-01-012020-01-310001656536dbtx:SeriesAConvertiblePreferredStockMember2020-12-310001656536us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001656536us-gaap:CommonStockMember2022-01-012022-03-310001656536srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-01-010001656536us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001656536dbtx:UnvestedRestrictedStockUnitsMember2022-01-012022-09-300001656536us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001656536us-gaap:CommonStockMember2022-04-012022-06-300001656536us-gaap:RetainedEarningsMember2022-04-012022-06-300001656536us-gaap:AccountingStandardsUpdate202104Member2022-09-300001656536dbtx:USAgencyBondsMemberdbtx:CurrentMember2022-09-300001656536us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001656536us-gaap:RestrictedStockMember2021-01-012021-09-30dbtx:Investmentxbrli:purexbrli:sharesdbtx:Voteiso4217:USDiso4217:USDxbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

 

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________

Commission File Number: 001-40030

 

Decibel Therapeutics, Inc.

(Exact name of Registrant as specified in its Charter)

 

 

Delaware

46-4198709

( State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

1325 Boylston Street, Suite 500

Boston, Massachusetts

02215

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 370-8701

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.001 per share

 

DBTX

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 1, 2022, the registrant had 24,964,502 shares of common stock, $0.001 par value per share, outstanding.

 

 


 

Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

Item 1.

Financial Statements (Unaudited)

5

 

Condensed Consolidated Balance Sheets

5

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

6

 

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ (Deficit) Equity

7

 

Condensed Consolidated Statements of Cash Flows

9

 

Notes to Unaudited Condensed Consolidated Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

24

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

37

Item 4.

Controls and Procedures

37

 

 

 

PART II.

OTHER INFORMATION

 

Item 1.

Legal Proceedings

38

Item 1A.

Risk Factors

38

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

91

Item 3.

Defaults Upon Senior Securities

91

Item 4.

Mine Safety Disclosures

91

Item 5.

Other Information

91

Item 6.

Exhibits

92

Signatures

93

 

 

 

i


 

Cautionary Note Regarding Forward-Looking Statements and Industry Data

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

the initiation, timing, progress and results of our current research and development programs, preclinical studies and clinical trials;
our estimates regarding expenses, future revenue, capital requirements and need for additional financing;
our plans to develop our product candidates and programs;
the timing of and our ability to submit applications for, obtain and maintain regulatory approvals for our product candidates;
our estimates regarding the potential patient populations for our product candidates and programs;
our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents and available-for-sale securities;
the potential advantages of our product candidates and programs;
the potential advantages of our platform;
the rate and degree of market acceptance and clinical utility of our product candidates and programs;
our estimates regarding the potential market opportunity for our product candidates and programs;
our commercialization, marketing and manufacturing capabilities and strategy;
our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;
the impact of government laws and regulations;
our competitive position;
developments relating to our competitors and our industry;
our ability to maintain and establish collaborations or obtain additional funding;
the potential direct or indirect impact of the COVID-19 pandemic on our business; and
our expectations regarding the time during which we will be an emerging growth company under the Jumpstart our Business Startup Acts of 2012.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in the “Risk Factor Summary” below and in Part II, Item 1A. “Risk Factors,” that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed or incorporated by reference hereto completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report on Form 10-Q, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

2


 

This Quarterly Report on Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. The market data used in this Quarterly Report on Form 10-Q involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Although we are responsible for the disclosure contained in this Quarterly Report on Form 10-Q and we believe the information from industry publications and other third-party sources included in this Quarterly Report on Form 10-Q is reliable, such information is inherently imprecise. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.

Risk Factor Summary

 

Our business is subject to a number of risks of which you should be aware before making an investment decision. Below we summarize what we believe to be the principal risks facing our business, in addition to the risks described more fully in Part II, Item 1A. “Risk Factors” of this Quarterly Report on Form 10-Q and other information included in this report. The risks and uncertainties described below are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations.

 

If any of the following risks occur, our business, financial condition and results of operations and future growth prospects could be materially and adversely affected, and the actual outcomes of matters as to which forward-looking statements are made in this report could be materially different from those anticipated in such forward-looking statements.

 

We have incurred significant losses since our inception, have no products approved for sale and we expect to incur substantial losses for the foreseeable future and may never achieve or maintain profitability;

 

We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our research and development programs or commercialization efforts;

 

The COVID-19 pandemic disrupted our ongoing Phase 1b clinical trial of DB-020 and has affected and may in the future affect our ability to initiate and complete preclinical studies, delay the initiation of our planned clinical trials or future clinical trials, disrupt regulatory activities, disrupt our manufacturing and supply chain or have other adverse effects on our business and operations. In addition, this pandemic has caused substantial disruption to global supply chains and may adversely impact economies worldwide, both of which could result in adverse effects on our business, operations and ability to raise capital;

 

Our limited operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability;

 

We are early in our development efforts. Our business is dependent on our ability to advance our lead gene therapy product candidate, DB-OTO, and our other current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them. If we are unable to complete clinical development, obtain regulatory approval for or commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed;

 

Clinical development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate;

 

Gene therapy is an emerging field of drug development that poses many risks. We have only limited prior experience in gene therapy research and no prior experience in gene therapy clinical development. Our lack of experience and the limited patient populations for our gene therapy programs may limit our ability to be successful or may delay our development efforts;

 

3


 

If we experience delays or difficulties in participant enrollment for clinical trials, our research and development efforts and the receipt of necessary regulatory approvals could be significantly delayed or prevented;

 

Our product candidates or the process for administering our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval;

 

The manufacture of gene therapy products is complex and difficult and is subject to a number of scientific and technical risks, some of which are common to the manufacture of drugs and biologics and others of which are unique to the manufacture of gene therapies. We could experience manufacturing problems that result in delays in our gene therapy development or commercialization programs;

 

We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research, preclinical and clinical testing, and these third parties may not perform satisfactorily;

 

We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do;

 

Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could harm our business; and

 

Our rights to develop and commercialize any product candidates are subject and may in the future be subject, in part, to the terms and conditions of licenses granted to us by third parties. If we fail to comply with our obligations under our current or future intellectual property license agreements, including applicable diligence milestones, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.

4


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

DECIBEL THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share and per share data)

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

36,682

 

 

$

36,455

 

Available-for-sale securities

 

 

75,264

 

 

 

112,292

 

Accounts receivable from related party

 

 

10,000

 

 

 

11,402

 

Prepaid expenses and other current assets

 

 

4,340

 

 

 

4,042

 

Total current assets

 

 

126,286

 

 

 

164,191

 

Available-for-sale securities, long-term

 

 

 

 

 

13,547

 

Property and equipment, net

 

 

4,553

 

 

 

5,611

 

Right-of-use asset, operating

 

 

10,290

 

 

 

 

Right-of-use asset, finance

 

 

84

 

 

 

 

Other assets

 

 

1,060

 

 

 

1,128

 

Total assets

 

$

142,273

 

 

$

184,477

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

3,031

 

 

$

4,012

 

Accrued expenses and other current liabilities

 

 

8,371

 

 

 

7,712

 

Deferred collaboration liability, current

 

 

8,353

 

 

 

8,118

 

Deferred rent and lease incentive obligation, current

 

 

 

 

 

696

 

Operating lease liability, current

 

 

3,545

 

 

 

 

Finance lease liability, current

 

 

74

 

 

 

 

Total current liabilities

 

 

23,374

 

 

 

20,538

 

Long-term liabilities:

 

 

 

 

 

 

Deferred collaboration liability, long-term

 

 

9,220

 

 

 

16,431

 

Deferred rent and lease incentive obligation, long-term

 

 

 

 

 

4,208

 

Operating lease liability, long-term

 

 

11,104

 

 

 

 

Other long-term liabilities

 

 

1,761

 

 

 

1,611

 

Total liabilities

 

 

45,459

 

 

 

42,788

 

Commitments and contingencies (Note 7)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued
   and outstanding at September 30, 2022 and December 31, 2021

 

 

 

 

 

 

Common stock, $0.001 par value; 200,000,000 shares authorized, 24,964,502 shares
   issued and
24,962,875 shares outstanding at September 30, 2022; 200,000,000 shares authorized,
   
24,964,520 shares issued and 24,951,983 shares outstanding at December 31, 2021

 

 

25

 

 

 

25

 

Additional paid-in capital

 

 

358,871

 

 

 

356,308

 

Accumulated other comprehensive loss

 

 

(503

)

 

 

(132

)

Accumulated deficit

 

 

(261,579

)

 

 

(214,512

)

Total stockholders’ equity

 

 

96,814

 

 

 

141,689

 

Total liabilities and stockholders’ equity

 

$

142,273

 

 

$

184,477

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5


 

DECIBEL THERAPEUTICS, INC.

CONDENSED conSOLIDATED Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share data)

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

10,030

 

 

$

9,020

 

 

$

28,737

 

 

$

21,867

 

General and administrative

 

 

6,319

 

 

 

5,680

 

 

 

18,734

 

 

 

15,462

 

Total operating expenses

 

 

16,349

 

 

 

14,700

 

 

 

47,471

 

 

 

37,329

 

Loss from operations

 

 

(16,349

)

 

 

(14,700

)

 

 

(47,471

)

 

 

(37,329

)

Other income:

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

374

 

 

 

33

 

 

 

532

 

 

 

141

 

Total other income, net

 

 

374

 

 

 

33

 

 

 

532

 

 

 

141

 

Net loss before provision for income taxes

 

 

(15,975

)

 

 

(14,667

)

 

 

(46,939

)

 

 

(37,188

)

Provision for income taxes

 

 

(30

)

 

 

(1,732

)

 

 

(128

)

 

 

(1,732

)

Net loss

 

$

(16,005

)

 

$

(16,399

)

 

$

(47,067

)

 

$

(38,920

)

Cumulative dividends on convertible preferred stock

 

 

 

 

 

 

 

 

 

 

 

(2,309

)

Net loss attributable to common stockholders

 

$

(16,005

)

 

$

(16,399

)

 

$

(47,067

)

 

$

(41,229

)

Net loss per share attributable to common stockholders, basic and diluted

 

$

(0.64

)

 

$

(0.66

)

 

$

(1.89

)

 

$

(2.00

)

Weighted average shares of common stock outstanding, basic and diluted

 

 

24,961,873

 

 

 

24,874,738

 

 

 

24,958,597

 

 

 

20,661,879

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(16,005

)

 

$

(16,399

)

 

$

(47,067

)

 

$

(38,920

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale securities, net of tax of $0

 

 

85

 

 

 

3

 

 

 

(371

)

 

 

9

 

Total other comprehensive income (loss)

 

 

85

 

 

 

3

 

 

 

(371

)

 

 

9

 

Comprehensive loss

 

$

(15,920

)

 

$

(16,396

)

 

$

(47,438

)

 

$

(38,911

)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6


 

DECIBEL THERAPEUTICS, INC.

CONDENSED CONSOLIDATED Statements of CONVERTIBLE PREFERRED STOCK AND Stockholders’ (Deficit) EQUITY

(Unaudited)

(In thousands, except share data)

 

 

 

Series A
Convertible Preferred
Stock

 

 

Series B
Convertible Preferred
Stock

 

 

Series C
Convertible Preferred
Stock

 

 

Series D
Convertible Preferred
Stock

 

 

 

Common Stock

 

 

Additional
Paid-In

 

 

Accumulated
Other
Comprehensive

 

 

Accumulated

 

 

Total
Stockholders’
(Deficit)

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

(Loss) Income

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2020

 

 

57,758,734

 

 

$

16,176

 

 

 

12,500,000

 

 

$

5,700

 

 

 

37,528,581

 

 

$

16,759

 

 

 

31,740,554

 

 

$

54,456

 

 

 

 

521,052

 

 

$

1

 

 

$

107,908

 

 

$

(1

)

 

$

(162,689

)

 

$

(54,781

)

Issuance of common stock upon
   exercise of stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,773

 

 

 

 

 

 

17

 

 

 

 

 

 

 

 

 

17

 

Vesting of restricted common stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10,202

 

 

 

 

 

 

4

 

 

 

 

 

 

 

 

 

4

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

646

 

 

 

 

 

 

 

 

 

646

 

Issuance of Series D convertible
    preferred stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

15,870,209

 

 

 

27,400

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Conversion of convertible preferred
   stock into common stock upon
   completion of initial public offering

 

 

(57,758,734

)

 

 

(16,176

)

 

 

(12,500,000

)

 

 

(5,700

)

 

 

(37,528,581

)

 

 

(16,759

)

 

 

(47,610,763

)

 

 

(81,856

)

 

 

 

16,662,011

 

 

 

17

 

 

 

120,474

 

 

 

 

 

 

 

 

 

120,491

 

Issuance of common stock upon
   completion of initial public
   offering, net of commissions,
   underwriting discounts
   and offering costs of $
13,137

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

7,662,000

 

 

 

7

 

 

 

124,772

 

 

 

 

 

 

 

 

 

124,779

 

Unrealized loss on available-for-sale
   securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(20

)

 

 

 

 

 

(20

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(10,870

)

 

 

(10,870

)

Balance at March 31, 2021

 

 

 

 

$

 

 

 

 

 

$

 

 

 

 

 

$

 

 

 

 

 

$

 

 

 

 

24,859,038

 

 

$

25

 

 

$

353,821

 

 

$

(21

)

 

$

(173,559

)

 

$

180,266

 

Issuance of common stock upon
    exercise of stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

354

 

 

 

 

 

 

1

 

 

 

 

 

 

 

 

 

1

 

Vesting of restricted common stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9,425

 

 

 

 

 

 

5

 

 

 

 

 

 

 

 

 

5

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

764

 

 

 

 

 

 

 

 

 

764

 

Unrealized gain on available-for-sale
   securities